ClinicalTrials.gg
CompletedNCT01064726Updated Jun 2, 2010

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

A Phase 1 interventional study of Ibuprofen and Fluticasone propionate in Allergic Rhinitis, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-06-02.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.

Enrollment
30th of 34
18 · median 63
Started
2009
with 1 other
Phase 1
6 of 34
none open now
Registered
19th of 34
by date

Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 30th largest by enrollment, is one of 2 that started in 2009, is one of 6 in phase 1, and was the 19th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing fluticasone in Rhinitis, Allergic as a file.
02

Study summary

After a nasal allergen challenge it should be possible to measure markers of inflammation that may be useful to assess the properties of future drugs. If these markers are reproducible and impacted by the study drugs they could be useful for future drug development.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

Keywords

  • Allergic Rhinitis Nasal Allergen Challenge Inflammatory Markers
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with seasonal allergic rhinitis (out of season).
  • Sensitive to ragweed skin prick test and screening nasal allergen challenge.

Exclusion criteria

Exclusion Criteria:

  • Subjects with significant concomitant diseases.
  • Subjects with symptoms of allergic rhinitis in 2 weeks prior to screening.
  • Female subjects that are pregnant or nursing. Subjects with to study drugs or allergen challenge.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    Drug: Ibuprofen

  • Experimental
    Fluticasone propionate

    Drug: Fluticasone propionate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Nasal inflammatory markers

    Time frame: 8h 45 min post dose

  2. Acoustic rhinometry

    Time frame: 8h 45 min post dose

  3. Nasal symptom scores

    Time frame: 8h 45 min post dose

Secondary outcomes

  1. Spirometry

    Time frame: 8h 45 min post dose

07

Study locations

1 site
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2009
First posted
Feb 8, 2010
Start
Oct 2009
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Jun 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01064726
Lead sponsor
Pfizer
First posted
Feb 8, 2010
Start date
Oct 2009
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Jun 2, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Fluticasone

Start the discussion